The CEOs of both Bristol-Myers Squibb (NYSE:BMY) and Teva Pharmaceutical Industries (NYSE:TEVA) have indicated that they're looking to make deals at the moment. In this video, Motley Fool health-care analyst David Williamson looks at both companies and how successful some of their recent mergers and acquisitions were. He also examines several possible takeover candidates and discusses just how likely each might be for an acquisition by BMY or TEVA. Finally, David tells investors which of the two he sees as stronger at the moment, and how this pricey bull market may affect the companies' decisions.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.